EUVIMEDEUVIMED entdecken
Open Access

EGFR-TKIs with or without stereotactic body radiotherapy to primary lesion in the advanced EGFR-mutated non-small cell lung cancer

Ze Yuan, Dan Tao, Dingyi Yang, Yong Jiang, Erha Munai, Siwei Zeng, Wei Zhou, Yongzhong Wu

Journal of Thoracic Disease · 2025-10 · 17 (10) · 8442-8457

DOI: 10.21037/jtd-2025-635 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thoracic Disease, 2025-10. Verfasst von Ze Yuan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains challenging due to resistance to EGFR tyrosine kinase inhibitors (TKIs). This study evaluated the efficacy and safety of combining EGFR-TKIs with stereotactic body radiotherapy (SBRT) to primary lesions in EGFR-mutant NSCLC patients.

Methods

This was a retrospective analysis with 58 EGFR-mutant NSCLC patients who were treated from 2018 to 2023; the included patients were divided into TKIs plus SBRT (n=15) and TKI alone (n=43) groups. Clinical outcomes, including progression-free survival (PFS), overall survival (OS), and toxicities, were assessed.

Results

A total of 485 patients with advanced NSCLC were screened, and 58 patients were eligible for enrollment in this study. Of the 58 eligible patients, 15 (25.9%) received EGFR-TKI treatment plus SBRT to the lung primary tumor and 43 (74.1%) received EGFR-TKI treatment alone. The TKIs plus SBRT group exhibited a significant extension in PFS compared to the TKIs alone group median PFS [54.9 vs. 10.2 months, hazard ratio (HR) 0.21, 95% confidence interval (CI): 0.12-0.39, P

Schlagwörter

Stichwörter der Autor:innen

Non-small cell lung cancer (NSCLC)epidermal growth factor receptor (EGFR)primary lesionstereotactic body radiation therapytyrosine kinase inhibitors (TKIs)

Autor:innen und Institutionen

  • Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  • Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
  • Medical School of Chongqing University, Chongqing University, Chongqing, China.

Zitieren

APA

Yuan, Z., Tao, D., Yang, D., Jiang, Y., Munai, E., Zeng, S., Zhou, W., & Wu, Y. (2025). EGFR-TKIs with or without stereotactic body radiotherapy to primary lesion in the advanced EGFR-mutated non-small cell lung cancer. Journal of Thoracic Disease, 17(10), 8442-8457. https://doi.org/10.21037/jtd-2025-635

Vancouver

Yuan Z, Tao D, Yang D, Jiang Y, Munai E, Zeng S, et al. EGFR-TKIs with or without stereotactic body radiotherapy to primary lesion in the advanced EGFR-mutated non-small cell lung cancer. Journal of Thoracic Disease. 2025;17(10):8442-8457. doi:10.21037/jtd-2025-635

BibTeX
@article{Yuan2025,
  author = {Yuan, Ze and Tao, Dan and Yang, Dingyi and Jiang, Yong and Munai, Erha and Zeng, Siwei and Zhou, Wei and Wu, Yongzhong},
  title = {EGFR-TKIs with or without stereotactic body radiotherapy to primary lesion in the advanced EGFR-mutated non-small cell lung cancer},
  journal = {Journal of Thoracic Disease},
  year = {2025},
  volume = {17},
  number = {10},
  pages = {8442--8457},
  doi = {10.21037/jtd-2025-635}
}
Kostenlos starten →